Plain-English translation of NCT04298723 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing two different ways to protect people with atrial fibrillation (an irregular heartbeat) who have experienced a brain bleed. One option is a small device called Watchman that is implanted in your heart to reduce stroke risk. The other is taking a newer blood-thinning medication (NOAC) by mouth. The trial wants to find out which approach works better and is safer for people in your situation.
People with an irregular heartbeat face a higher risk of stroke, so they usually need blood thinners to protect themselves. However, blood thinners can increase the risk of another brain bleed. This trial exists to find the safest and most effective way to protect stroke risk without causing another bleed in people who have already experienced one.
You likely qualify if…
You likely don't qualify if…
If you are randomly assigned to the device group, you will undergo a procedure to have the Watchman device implanted in your heart, after which you may be able to stop taking blood thinners. If you are assigned to the medication group, you will take a blood-thinning medication as prescribed and have regular follow-up visits to monitor your health. Either way, you will be followed and checked regularly throughout the study to see how well your treatment is working and to watch for any side effects.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
Germany